Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 308 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atorvastatin (Lipitor) Clear all
Completed Phase 3 Interventional

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

NCT00134498
View directory record Official record
Conditions
Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
39
States / cities
Anaheim, California • Huntington Beach, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

NCT02374047
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CAT-2054, Placebo, CAT-2054-C, Atorvastatin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 2, 2026, 2:29 AM EDT
Recruiting Phase 2 Interventional

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

NCT04915183
View directory record Official record
Conditions
Hearing Loss, Head and Neck Cancer
Interventions
Placebo, Atorvastatin
Other · Drug
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 100 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Not applicable Interventional Results available

Effect of Succinylcholine on Patients Using Statins

NCT00986583
View directory record Official record
Conditions
Pain
Interventions
Succinylcholine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 2, 2026, 2:29 AM EDT
Withdrawn Phase 1 Interventional

Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI

NCT01605344
View directory record Official record
Conditions
Advanced Adenocarcinoma of the Colon or Rectum
Interventions
FOLFIRI., Atorvastatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

A Study in People With High Cholesterol

NCT00133380
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PPAR alpha, atorvastatin, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Fayetteville, Arkansas • Stockton, California • Highlands Ranch, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2007 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

NCT01161082
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
REGN727(SAR236553)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

NCT00138762
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Oro Valley, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 2, 2026, 2:29 AM EDT
Terminated Not applicable Interventional Results available

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

NCT00770679
View directory record Official record
Conditions
Diabetes
Interventions
lipitor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 2, 2026, 2:29 AM EDT
Not listed Not applicable Interventional

The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A

NCT00004564
View directory record Official record
Conditions
Hypercholesterolemia, Thrombosis
Interventions
Clopidogrel, Atorvastatin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 2:29 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

NCT05331053
View directory record Official record
Conditions
Endometriosis
Interventions
Atorvastatin
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 3 Interventional

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

NCT00134173
View directory record Official record
Conditions
Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
127
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 2, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional

Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome

NCT00004466
View directory record Official record
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

NCT02641899
View directory record Official record
Conditions
Healthy
Interventions
ITCA 650 20/60 mcg/day, Acetaminophen, Atorvastatin, Lisinopril, Warfarin, Digoxin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing CoQ10 Levels While Taking 3 Different Statins

NCT01660191
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Pitavastin 4mg, Atorvastatin 20mg, Rosuvastatin 5mg
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

NCT02081638
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Aspirin, Atorvastatin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

NCT06948747
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 2, 2026, 2:29 AM EDT
Withdrawn No phase listed Observational

Genetic Influence on Statin Pharmacodynamics

NCT01569854
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Dyslipidemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Statin Therapy in Young Adult Survivors of Childhood Cancer

NCT01733953
View directory record Official record
Conditions
Cardiovascular Disease, Childhood ALL, Childhood NHL
Interventions
Atorvastatin, Sugar Pill (Placebo)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 39 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

NCT01112670
View directory record Official record
Conditions
Healthy
Interventions
Sitagliptin, atorvastatin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Phase 4 Interventional Results available

Statin Therapy in Heart Failure: Potential Mechanisms of Benefit

NCT00233480
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
atorvastatin, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 2, 2026, 2:29 AM EDT
Completed Not applicable Interventional

Pediatric Kidney Transplant Without Calcineurin Inhibitors

NCT00023231
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 2, 2026, 2:29 AM EDT
Not listed Phase 2 Interventional

Statins and Breast Cancer Biomarkers

NCT00914017
View directory record Official record
Conditions
Breast Cancer
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
7
States / cities
San Francisco, California • Newark, Delaware • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 2, 2026, 2:29 AM EDT